key: cord-0848253-fjy6yoc7 authors: Alpert, Naomi; Taioli, Emanuela title: Re: Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis date: 2021-03-03 journal: J Natl Cancer Inst DOI: 10.1093/jnci/djab030 sha: 106bc62ae57b1b1676fa862921b147213c1e07b8 doc_id: 848253 cord_uid: fjy6yoc7 nan A recent systematic review and meta-analysis of 15 studies by Zhang, et al (1) showed a statistically significantly higher fatality rate for coronavirus disease 2019 (COVID-19) patients with cancer than for COVID-19 patients without cancer. We want to point out the methodological limitations of current published studies on COVID-19 cancer patients' outcomes, mainly the lack of controls and inclusion of inappropriate controls, such as other cancer types. Of the studies in this meta-analysis, only 3 included non-cancer controls, with pooled fatality rates of 23.4% and 5.9% for cancer and non-cancer patients, and high statistical heterogeneity (87% and 85% respectively). One of the three studies reported unadjusted survival rates for 13 hematological cancer patients and 11 hospitalized healthcare workers (2) . As expected, the healthcare workers fared better than other study controls, likely due to a healthy worker effect (3) . This study contributed the most extreme fatality rates for both cancer (62%) and non-cancer cases (0%). A sensitivity analysis of the two remaining studies with matched controls shows cancer and non-cancer fatality rates of 16% and 8% respectively; however, these studies are restricted to China, and may not be generalizable elsewhere. We want to underline the unique aspects of COVID-19 infected cancer patients that should guide the choice of appropriate controls. Cancer patients are likely to be older, male, and have more comorbidities than non-cancer patients, factors consistently shown to be associated with poor COVID-19 outcomes (4); thus, appropriate matching or multivariate adjustments are critical for obtaining valid relative estimates. We recently published higher COVID-19 case fatality rates in cancer than non-cancer hospitalized patients (30.6% and 24.8%) (5). However, when directly compared, after adjusting for age sex, and comorbidities, cancer patients had statistically significantly higher odds of morbidity, but no statistically significant difference in short term mortality. 3 Studies need to include non-cancer controls with equal COVID-19 exposure opportunity. For example, cancer patients have increased healthcare interactions, and therefore, more chances for incidental COVID-19 diagnosis; controls should be selected from similar care settings to reduce this bias. The strategy of drawing non-cancer controls from the same population as cancer cases also reduces the confounding effect of the novel more transmissible or debilitating virus variants, which we know vary geographically. Furthermore, this strategy would also address the poor COVID-19 outcomes directly related to high community case rate (6) and consequent hospital strain. While it is urgently important to identify factors associated with poor COVID-19 outcomes, and protect those most vulnerable, it is also imperative to use appropriate epidemiologic design to avoid bias and confounding to accurately quantify morbidity and mortality. This work was supported in part by the National Cancer Institute (P30CA196521) Role of the Funder: The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript Disclosures: The authors declare no potential conflicts of interest Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute COVID-19 in persons with haematological cancers A review of the healthy worker effect in occupational epidemiology Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic Not applicable.